Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer

[1]  S. Joel,et al.  A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer , 2002, British Journal of Cancer.

[2]  C. McArdle,et al.  Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial , 2002, The Lancet.

[3]  E. Van Cutsem,et al.  Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Sargent,et al.  Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. , 2001, The New England journal of medicine.

[5]  M. Seymour,et al.  Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. , 2001, The New England journal of medicine.

[6]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[7]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[8]  J. Lotz,et al.  CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. , 1999, European journal of cancer.

[9]  M. Ychou,et al.  Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Lotz,et al.  Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. , 1999, European journal of cancer.

[11]  D. Kerr,et al.  Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (De Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer. , 1999 .

[12]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[13]  M. Ychou,et al.  A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer. , 1998, American journal of clinical oncology.

[14]  C. Tournigand,et al.  A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). , 1998, European journal of cancer.

[15]  S. Guichard,et al.  Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. , 1998, Biochemical pharmacology.

[16]  W. Hiddemann,et al.  Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Rougier,et al.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. V. Von Hoff,et al.  Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Erlichman,et al.  A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A PROSPECTIVE, RANDOMISED , 2004 .

[21]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Louvet,et al.  Sequential cisplatin-doxorubicin, early debulking surgery and intraperitoneal chemotherapy in advanced ovarian cancer. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). , 1992, European journal of cancer.